Last update 01 Nov 2024
Hubei Dongsheng Pharmaceutical Co. Ltd.

Hubei Dongsheng Pharmaceutical Co. Ltd.

Private Company|
2003|
Hubei Sheng, China
|
250-500
|
www.ttmyy.com

Overview

Tags

Eye Diseases
Nervous System Diseases
Immune System Diseases
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases1
Infectious Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug5
Chemical drugs1
Top 5 TargetCount
30S subunit(30S ribosomal subunit)1
ADRA2(Adrenergic receptors alpha-2)1

Related

6
Drugs associated with Hubei Dongsheng Pharmaceutical Co. Ltd.
Pirenoxine Sodium
Target-
Mechanism-
Active Org.
Hubei Dongsheng Pharmaceutical Co. Ltd.Hubei Dongsheng Pharmaceutical Co. Ltd.
Originator Org.
Hubei Dongsheng Pharmaceutical Co. Ltd.Hubei Dongsheng Pharmaceutical Co. Ltd.
Active Indication
Cataract
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
CN
First Approval Date01 Jan 1981
Cromolyn Sodium
Target-
Mechanism
Glial cells modulators [+1]
Active Org.
Hubei Dongsheng Pharmaceutical Co. Ltd.Hubei Dongsheng Pharmaceutical Co. Ltd. [+3]
Originator Org.
SanofiSanofi
Active Indication
Food Hypersensitivity [+2]
Inactive Indication
Amyotrophic Lateral Sclerosis [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
IE
First Approval Date01 Nov 1980
Clonidine Hydrochloride
Target
ADRA2
Mechanism
ADRA2 agonists
Active Org.
Shandong Dayin Oceanic Biochemicals Co. Ltd.Shandong Dayin Oceanic Biochemicals Co. Ltd. [+10]
Originator Org.
Boehringer Ingelheim GmbHBoehringer Ingelheim GmbH
Active Indication
Attention Deficit Disorder With Hyperactivity [+8]
Inactive Indication
Chemotherapy oral mucositis [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date15 May 1969
1
Clinical Trials associated with Hubei Dongsheng Pharmaceutical Co. Ltd.
CTR20241423 / RecruitingPhase 1
一项评估GPN00884滴眼液在健康成人受试者中单次及多次给药后安全性、耐受性和药代动力学特征的随机、双盲、安慰剂平行对照、剂量递增的I期临床研究
[Translation] A randomized, double-blind, placebo-controlled, dose-escalating Phase I clinical study to evaluate the safety, tolerability and pharmacokinetic characteristics of GPN00884 eye drops after single and multiple doses in healthy adult subjects
100 Clinical Results associated with Hubei Dongsheng Pharmaceutical Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Hubei Dongsheng Pharmaceutical Co. Ltd.
Login to view more data
100 Deals associated with Hubei Dongsheng Pharmaceutical Co. Ltd.
Login to view more data
100 Translational Medicine associated with Hubei Dongsheng Pharmaceutical Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
5
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Pirenoxine Sodium
Cataract
More
Approved
Clonidine Hydrochloride
 ( ADRA2 )		Ocular Hypertension
More
Approved
Pirenoxine
Cataract
More
Approved
Neomycin Sulfate
 ( 30S subunit )		Eye Infections
More
Approved
Cromolyn Sodium
Conjunctivitis, Allergic
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free